Jing Zhao

Education

Ph.D., biology, Baylor College of Medicine; M.S., biostatistics, Harvard T.H. Chan School of Public Health; B.S., biological science and biotechnology, Tsinghua University, China

Summary of Experience

Dr. Zhao draws on her background in biology and biostatistics in her research on the value of health care products and her work on analytics across the product life cycle. She has broad experience with the development and implementation of health economics and outcomes research (HEOR) strategies in a number of therapeutic areas, including diabetes, oncology, immunology, infectious diseases, and hematology. Dr. Zhao applies advanced research methods for health care data to real-world evidence development, individualized medicine, predictive analytics, and cost-effectiveness analysis. Her work has been used to inform health care regulators and payers in US and global markets, published in peer-reviewed journals, and presented at clinical and economic research conferences.

Selected Publishing

• Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma

  Journal of Comparative Effectiveness Research, 2021
  2021

  Parikh ND, Marshall A, Betts KA, Song J, Zhao J, Yuan M, Wu A, Huff KD, Kim R

  Health Care
• Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data

  Journal of the American Academy of Dermatology, 2021
  2021

  Shear NH, Betts KA, Soliman AM, Joshi A, Wang Y, Zhao J, Gisondi P, Sinvhal R, Armstrong AW

  Health Care
• Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84)

  The Journal of Clinical Endocrinology and Metabolism, 2020
  2020

  Chen KS, Gosmanova EO, Curhan GC, Ketteler M, Rubin M, Swallow E, Zhao J, Wang J, Sherry N, Krasner A, Bilezikian JP

  Health Care
• Prevalence of chronic respiratory morbidity, length of stay, inpatient readmissions, and costs among extremely preterm infants with bronchopulmonary dysplasia

  Expert Review of Pharmacoeconomics & Outcomes Research, 2020
  2020

  Mowitz ME, Mangili A, Han L, Ayyagari R, Gao W, Wang J, Zhao J, Sarda SP

  Health Care
• Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma

  Clinical Therapeutics, 2019
  2019

  Telford C, Kabadi SM, Abhyankar S, Song J, Signorovitch J, Zhao J, Yao Z

  Health Care
• Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America

  Advances in Therapy, 2019
  2019

  Muniz DQ, Ratto B, Yang H, Zhao J, Jenkins M, Signorovitch J, Dezzani L, Salman P, Medina ML, Lopera D, Lerzo G, Del Castillo C, Chacon M, Martin A, Campos-Gomez S

  Health Care
• Health Care Burden of Bronchopulmonary Dysplasia Among Extremely Preterm Infants

  Frontiers in Pediatrics, 2019
  2019

  Mowitz ME, Ayyagari R, Gao W, Zhao J, Mangili A, Sarda SP

  Health Care
• Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome

  Therapeutics and Clinical Risk Management. 2018 Jul 25;14:1267-1277
  2018

  Chen KS, Xie J, Tang W, Zhao J, Jeppesen PB, Signorovitch JE

  Health Care
• Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data

  BMJ Open. 2018 Aug 17;8(8):e021642
  2018

  Li J, Sasane M, Zhang J, Zhao J, Ricculli ML, Yao Z, Redhu S, Signorovitch J

  Health Care
• Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis

  Advances in Therapy. 2018 Jul;35(7):1035-1048
  2018

  Li J, Sasane M, Zhao J, García-Horton V, Zhang P, Ricculli ML, Zhou ZY, Signorovitch J

  Health Care
• Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study

  Diabetes Therapy. Jun 2017;8(3):555-571
  2017

  Zhou Z, Chaudhari P, Yang H, Fang AP, Zhao J, Law EH, Wu EQ, Jiang R, Seifeldin R

  Health Care
• A Risk Score for Fluconazole Failure among Patients with Candidemia

  Antimicrobial Agents Chemotherapy. 2017 Apr 24;61(5). pii: e02091-16. doi: 10.1128/AAC.02091-16. Print 2017 May.
  2017

  Yang H, Ostrosky-Zeichner L, Harrington R, Azie N, Li N, Zhao J, Koo V, Wu EQ

  Health Care